SUMMARY Disturbances of humoral and cellular immunity are common in patients with idiopathic dilated cardiomyopathy and they may contribute to the initiation and maintenance of myocardial damage. HLA antigens were studied in 102 patients with dilated cardiomyopathy and a control hospital population. HLA-DR4 was significantly more common in patients with idiopathic cardiomyopathy (41 patients, 40%) than in the control group (123 patients, 24%). The distribution of other antigens was not significantly different in the two groups. The distribution of blood group antigens, immunoglobulin concentrations, and disease severity was similar in patients with the HLA-DR4 antigen and those without it.
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These results suggest that HLA-DR4 antigen may be a genetic marker for susceptibility to dilated cardiomyopathy.
Idiopathic dilated cardiomyopathy is a clinical entity of unknown and probably heterogeneous aetiology. In the search for pathogenetic mechanisms, considerable attention has been focused on the possibility that disturbed immunity may be important. '9 Several abnormalities in cellular'" and humoral 9 immunity have already been described in patients with idiopathic dilated cardiomyopathy and are thought to be triggered by an initial episode of myocardial damage (for example after viral infection) that sets the stage for an autoimmune response. Development of autoimmunity is the summation of diverse genetic traits that give rise to a genetic predisposition expressed both as an increased susceptibility to infectious (for example viral) agents and to organ specific autoimmune reactions.'0
In most reported cases a predisposition to autoimmune disease is under the control of immune response genes1"0 and as a result autoimmune disorders show preferential associations with the products of immunoglobulin, complement, or HLA genes. For example, there is a significant increase in the frequency of HLA-B27 antigens in ankylosing spondylitis, HLA-DR3/DR4 in juvenile diabetes mellitus, and HLA-DR3 in myasthenia gravis ( Accepted for publication 3 July 1989 antigens that leads to the pathological manifestations of organ-specific autoimmunity." Such expression may be induced in response to viral infection or as a result of the initial tissue damage induced by the putative initiating agent. To examine the possible role of immune response factors in the pathogenesis of idiopathic dilated cardiomyopathy, we compared the frequency ofhistocompatibility antigens A, B, C, and DR with that expected in a control population.
Patients and methods
We studied 102 white patients (aged 16-65, mean (SD) 43-8 (10)) with idiopathic dilated cardiomyopathy; none was alcoholic. There were 18 (17-6%) women. About 90% of these patients were of Northern European (predominantly Scandinavian) origin.
Cardiac symptoms had been present for 3-51 (1-0) years. There were no diseases known to be associated with specific HLA antigens (such as diabetes mellitus, ankylosing spondylitis, Graves' disease, myasthenia gravis, or rheumatoid arthritis). The severity of myocardial dysfunction in these patients was indicated by a low ejection fraction (4%), raised pulmonary capillary wedge pressure (26-8 (5) mm Hg), low cardiac index (2-1 (0 2) 1/min/m2), and high concentrations ofplasma noradrenaline 3.4 (0-4) nmol/l). We selected controls for this patient group from a local hospital population. Six hundred and seventeen individuals were typed for HLA A, B, and C loci and 511 for HLA-DR loci (mean age 48 (9) years and 316 (28%) were women).
Lymphocytes None of the p0 values was significant.
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group which both recessive and dominant modes of inheritance have been described.22 It is not known, however, how the genetic traits are expressed as myocardial dysfunction in cardiomyopathy. Although, in some cases, metabolic defects of the cardiac myocyte have been implicated, in others, an enhanced susceptibility to environmental agents or to immunological responses to them may be at fault. An immunological component was shown for the progression to chronic cardiac disease in experimental and human viral myocarditis.2324 It is widely assumed that many cases of dilated cardiomyopathy are the end result of a preceding viral infection the serological evidence for which has long since disappeared. It is suggested that the initial virus induced myocardial damage sets up an immunological reaction against intracellular constituents which further sustains and aggravates myocardial dysfunction. Immunological mechanisms would thus have a secondary role and contribute to a variable extent to the progression of the myopathic process. It is also possible, however, that genetically controlled immunological mechanisms participate more directly in the initiation of myocardial damage either through control of the susceptibility to the aetiological viral infection, or through modulation of the immunological response to the putative viral agents. There is precedent for both mechanisms: for example, it is known that histocompatibility antigens determine the cardiotoxicity of Coxsackie B viruses24 or their interaction with specific tissues. Also, experimentally induced myocarditis induced in mice through induction of antimyosin antibodies is largely determined by the H-2 locus. 25 This suggested that it would be useful to look for immunologically associated genetic markers of dilated cardiomyopathy in humans. The HLA antigens were selected because of their known participation in the regulation of immune responses and the previously reported association between specific haplotypes and autoimmune diseases. The results of our study suggest that the frequency of HLA-DR4 was significantly higher in patients with dilated cardiomyopathy than in controls. This accords with the results ofa smaller series reported by Anderson et We found no correlation in this study between the presence of HLA-DR4 and the severity or duration of the disease. This may not be unexpected if the association is a marker for susceptibility to the disease but does not influence its progression or severity-a situation that is common to autoimmune diseases. On the other hand, if HLA-DR4 is a marker for a specific pathogenetic pathway (that is antireceptor autoantibodies), there may be a correlation with disease severity within this subset of cardiomyopathy patients. The design of our study, which includes patients with severe haemodynamic impairment does not allow us unequivocally to exclude the possibility that HLA-DR4 positive patients have more severe disease or more rapid course. A prospective study of a population with a wider range of haemodynamic abnormalities is currently underway and should help resolve this issue.
